



November 7, 2024

Santen Announces Share Buyback

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; President and CEO: Takeshi Ito; hereinafter, Santen) announced that its Board of Directors resolved today to repurchase its own shares in accordance with Article 156 of the Companies Act (Japan), as applied pursuant to Article 165, paragraph 3.

1. Reasons for Repurchase of Own Shares

Santen aims to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment in accordance with the capital allocation policy in the medium-term management plan (FY2023-2025) dated on April 13, 2023. Based on this policy, Santen completed approximately JPY 28.6 billion of repurchase as announced on “Santen Announces Completion of Share Buyback” today. The Company also decided to make another repurchase of JPY 10.0 billion (maximum) to enhance capital efficiency based on a consideration of factors including investment opportunities.

2. Details of Repurchase

(1) Class of shares to be repurchased	Common shares
(2) Total number of shares to be repurchased	5,000,000 shares (maximum) *Representing 1.4% of the total number of shares outstanding (excluding treasury shares)
(3) Total amount of repurchase	10.0 billion yen (maximum)
(4) Period of repurchase	November 8, 2024 to March 21, 2025
(5) Method of repurchase	Open-market repurchase by discretionary trading method

Santen plans to cancel the treasury shares by its Board of Directors resolution in accordance with Article 178 of the Companies Act (Japan).

There is a possibility that some of the purchases may not be made depending on investment opportunities or market conditions.

(Reference) Treasury Shares Information as of October 31, 2024

Total number of shares outstanding (excluding treasury shares)	347,002,868 shares
Treasury shares	17,019,386 shares

The Company plans to cancel treasury shares on November 29, 2024. Please refer to the announcement on “Santen Announces Cancellation of Treasury Shares” disclosed today.

Contact:

Guillaume Sakuma

Global Head of IR, IR Group

E-mail: ir@santen.com

About Santen

As a specialized company dedicated to eye health, Santen aspires to contribute to the realization of “Happiness with Vision” by providing products and services to patients, consumers, and medical professionals around the world. Since its establishment, and guided by its CORE PRINCIPLE, “*Tenki ni sanyo suru*,” Santen has been committed to helping people maintain and improve their eye health for more than 130 years. Santen is engaged in the global research and development, manufacturing, and sales and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries and regions worldwide. Santen’s mission is to provide essential and significant value to patients and society in the prevention, diagnosis, and treatment of eye diseases through products and services created from its expertise in the ophthalmology field and from the patient's perspective. To create a future in which as many patients as possible can lead happy and fulfilling lives, Santen is committed to doing its utmost to realize a society in which people around the world can experience “Happiness with Vision.”

For more information, please visit Santen’s website <https://www.santen.com/en>.